老年类风湿关节炎患者联用甲氨蝶呤能否延长TNF抑制剂药物生存期:英国风湿病学会生物制剂注册研究分析
结果显示TNFi单药治疗与停药风险增加相关,但该劣势在≥75岁患者中不再显现;≥75岁单药治疗者因无效停药风险更低、因不良事件停药风险更高。
要点
- TNFi单药较联用MTX整体停药风险更高(HR 1.12),但该差异仅见于<75岁患者。
- ≥75岁患者TNFi单药因无效停药风险更低(HR 0.66),因不良事件停药风险更高(HR 1.41)。
- 老年RA患者TNFi治疗策略需权衡疗效与毒性,单药劣势在≥75岁人群不显著。
核心结论
- TNFi单药治疗与治疗失败风险增加相关,但该劣势在≥75岁老年RA患者中不再显现。
- ≥75岁患者接受TNFi单药治疗时因无效停药风险低于年轻患者,因不良事件停药风险更高。
研究设计与样本
- 基于英国风湿病学会生物制剂注册的前瞻性观察队列,纳入生物制剂初治并首次启用TNFi的患者。
- 按年龄<75岁和≥75岁分层,采用Cox比例风险模型比较单药与联用MTX的停药风险。
主要发现
- 上述结果经完整病例和多插补多因素调整分析支持。
临床怎么用
- 对于<75岁RA患者,TNFi治疗时应优先考虑联用MTX以改善药物生存。
- 对于≥75岁RA患者,TNFi单药治疗的劣势不显著,可结合合并症和耐受性个体化选择。
- 老年RA患者使用TNFi时需更关注不良事件导致的停药风险。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate drug survival with monotherapy compared with combination therapy with MTX in RA older adults. METHODS: Patients from the British Society for Rheumatology Biologics Register, a prospective observational cohort, who were biologic naïve and commencing their first TNF inhibitors (TNFi) were included. The cohort was stratified according to age: <75 and ≥75. Cox-proportional hazards models compared the risk of TNFi discontinuation from (i) any-cause, (ii) inefficacy and (iii) adverse events, between patients prescribed TNFi-monotherapy compared with TNFi MTX combination. RESULTS: The analysis included 15 700 patients. Ninety-five percent were <75 years old. Comorbidity burden and disease activity were higher in the ≥75 cohort. Fifty-two percent of patients discontinued TNFi therapy during the follow-up period. Persistence with therapy was higher in the <75 cohort. Patients receiving TNFi monotherapy were more likely to discontinue compared with patients receiving concomitant MTX [hazard rate 1.12 (1.06-1.18) P <0.001]. This finding only held true in patients <75 [hazard rate (HR) 1.11 (1.05-1.17) vs ≥75 [HR 1.13 (0.90-1.41)]. Examining TNFi discontinuation by cause revealed patients ≥75 receiving TNFi monotherapy were less likely to discontinue TNFi due to inefficacy [HR 0.66 (0.43-0.99) P=0.04] and more likely to discontinue therapy from adverse events [HR 1.41(1.02-1.96) P =0.04]. These results were supported by the multivariate adjustment in complete case and imputed analyses. CONCLUSION: TNFi monotherapy is associated with increased treatment failure. In older adults, the disadvantage of TNFi monotherapy on drug survival is no longer seen. Patients ≥75 have fewer discontinuations due to inefficacy than adverse events compared with younger patients. This likely reflects greater disposition to toxicity but perhaps also a decline in immunogenicity associated with immunosenescence.
引用
- Bechman K, Oke A, Yates M, et al. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2020. PMID: 31998962. doi:10.1093/rheumatology/kez671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。